- Home
- PMCB vs MULN Comparison
PMCB vs MULN Comparison
Compare PMCB & MULN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- MULN
- Stock Information
- Founded
- PMCB 1996
- MULN 2014
- Country
- PMCB United States
- MULN United States
- Employees
- PMCB N/A
- MULN N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- MULN Auto Manufacturing
- Sector
- PMCB Health Care
- MULN Consumer Discretionary
- Exchange
- PMCB Nasdaq
- MULN Nasdaq
- Market Cap
- PMCB 11.4M
- MULN 12.2M
- IPO Year
- PMCB N/A
- MULN N/A
- Fundamental
- Price
- PMCB $1.76
- MULN $4.01
- Analyst Decision
- PMCB
- MULN
- Analyst Count
- PMCB 0
- MULN 0
- Target Price
- PMCB N/A
- MULN N/A
- AVG Volume (30 Days)
- PMCB 27.2K
- MULN 510.8K
- Earning Date
- PMCB 03-17-2025
- MULN 02-19-2025
- Dividend Yield
- PMCB N/A
- MULN N/A
- EPS Growth
- PMCB N/A
- MULN N/A
- EPS
- PMCB 0.74
- MULN N/A
- Revenue
- PMCB N/A
- MULN $4,014,807.00
- Revenue This Year
- PMCB N/A
- MULN N/A
- Revenue Next Year
- PMCB N/A
- MULN N/A
- P/E Ratio
- PMCB $2.37
- MULN N/A
- Revenue Growth
- PMCB N/A
- MULN 996.94
- 52 Week Low
- PMCB $1.39
- MULN $3.96
- 52 Week High
- PMCB $2.58
- MULN $47,100.00
- Technical
- Relative Strength Index (RSI)
- PMCB 60.08
- MULN 22.53
- Support Level
- PMCB $1.57
- MULN $10.80
- Resistance Level
- PMCB $1.66
- MULN $21.00
- Average True Range (ATR)
- PMCB 0.12
- MULN 2.78
- MACD
- PMCB 0.02
- MULN 1.42
- Stochastic Oscillator
- PMCB 68.89
- MULN 0.29
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About MULN Mullen Automotive Inc.
Mullen Automotive Inc is engaged in manufacturing electric vehicles and building energy solutions. Its portfolio of vehicles is predominantly comprised of commercial trucks and other electric vehicles and includes; Mullen Class 1 Cargo Van, Mullen Three, Bollinger B4 Chassis Cab, and Mullen I-GO. The company's operating segments are Bollinger which derives maximum revenue, and Mullen Commercial.